Navigation Links
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
Date:12/27/2007

- Company continues U.S. pivotal trial discussions with FDA -

MENLO PARK, Calif., Dec. 27 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT), the developer of customizable drug-eluting stent (DES) systems, today announced that it has submitted its application to the designated European Notified Body for CE Mark approval of its Custom NX DES System.

XTENT's CE Mark application includes the XTENT design dossier and the drug formulation submission from Biosensors International Group. XTENT plans to begin European sales of the Custom NX system in the second half of 2008 through partnerships with leading regional distributors, following CE Mark approval.

"Completing our CE Mark filing is a major milestone toward achieving our goal of commercializing the Custom NX system in select European countries," said Gregory D. Casciaro, President and CEO of XTENT. "This submission further demonstrates Biosensors' commitment to the success of Biolimus A9(R) and the ongoing collaboration between the two companies."

XTENT is also continuing its work with the U.S. Food and Drug Administration (FDA) to fulfill the necessary requirements to gain approval to start the CUSTOM IV pivotal trial. The company filed an Investigational Device Exemption (IDE) in September. XTENT and Biosensors are in the process of responding to questions from the FDA. XTENT will provide an update as to the anticipated start of the CUSTOM IV trial once both companies have completed discussions with the FDA.

About the Custom NX DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier, both developed and supplied to XTENT by Biosensors International Group. The Custom NX delivery system enables separation at each 6mm segment and allows for the placement of up to 60mm of stent. XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of our most recent quarterly report on Form 10-Q for the quarter ended September 30, 2007. The quarterly report was filed with the SEC on November 2, 2007, and is available on our investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. XTENT Announces Third Quarter 2007 Financial Results
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
4. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
7. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
8. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
9. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
10. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
11. Gentiva(R) Health Services Files Universal Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... In just two ... Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so ... nearly 2,000 consumers (and counting) already backing the campaign. , “We are ...
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... The ... and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has ... law clerk for the firm, will concentrate her practice in elder law, Medicaid planning ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of Serenity ... MD. Judy says, “I am passionate about sharing Reiki as a holistic, complementary ... and challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: A ... God in congregations across the United States. “The Communion of Saints” is ... who has served congregations in seven states throughout his long career of devotion ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the addition ... Replacement Procedure By Technique, Repair Procedure By Technique, By Region, By ... ... forecasted to grow at a CAGR of 13.35% during 2016-2021 ... rising aging population, growth in population with heart disease and rising ...
(Date:3/23/2017)... , March 23, 2017 ... report created through extensive primary research (inputs from ... report aims to present the analysis of global ... Procedure (Replacement and Repair); Replacement Procedure By Technique ... By Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology: